Tibotec's novel TMC207 shows promise in multidrug-resistant TB
This article was originally published in Scrip
Tibotec's (J&J's) investigational antimycobacterial drug TMC207 has demonstrated efficacy in 48% of patients with multidrug-resistant tuberculosis in a Phase II study. The findings were published in the NEJM online on June 4th.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.